Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer.
Testing for HER2/neu in breast cancer at the time of primary diagnosis is now the standard of care. Accurate and standardized testing methods are of prime importance to ensure the proper classification of the patient's HER2/neu status. A meeting of pathologists from across Canada was convened to update the Canadian HER2/neu testing guidelines. This National HER2/neu Testing Committee reviewed the recently published American Society of Clinical Oncology/ College of American Pathologists (ASCO/CAP) guidelines for HER2/neu testing in breast cancer. The updated Canadian HER2/neu testing guidelines are based primarily on the ASCO/CAP guidelines, with some modifications. It is anticipated that widespread adoption of these guidelines will further improve the accuracy of HER2/neu testing in Canada.
Hanna
W
W
Anatomic Pathology, Sunnybrook Health Sciences Centre, Toronto, Ontario. Wedad.Hanna@sunnybrook.ca
O'malley
F P
FP
Barnes
P
P
Berendt
R
R
Gaboury
L
L
Magliocco
A
A
Pettigrew
N
N
Robertson
S
S
Sengupta
S
S
Têtu
B
B
Thomson
T
T
Am J Clin Pathol. 2003 Jul;120(1):86-92
12866377
J Clin Pathol. 2004 Mar;57(3):233-7
14990588
JAMA. 2004 Apr 28;291(16):1972-7
15113815
Clin Breast Cancer. 2004 Apr;5(1):63-9
15140287
N Engl J Med. 2005 Oct 20;353(16):1659-72
16236737
Science. 1987 Jan 9;235(4785):177-82
3798106
N Engl J Med. 2006 Feb 23;354(8):809-20
16495393
N Engl J Med. 2006 May 18;354(20):2103-11
16707747
J Clin Oncol. 2007 Jan 1;25(1):118-45
17159189
Science. 1986 Jun 27;232(4758):1644-6
3012781
N Engl J Med. 2005 Oct 20;353(16):1673-84
16236738